News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News ACC 2024 Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI Michael O'Riordan April 07, 2024
News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024
News Conference News ACC 2023 CRP More Predictive of Future Events Than LDL in Statin-Treated Patients Caitlin E. Cox March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study Todd Neale March 10, 2023
News Conference News ACC 2023 STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy L.A. McKeown March 04, 2023
News Conference News ACC 2023 Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III Shelley Wood March 04, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Conference News ACC 2020 Colchicine Cost-effective in Canada, and Even in the US: COLCOT Caitlin E. Cox March 28, 2020
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Conference News ACC 2019 Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom Michael O'Riordan March 20, 2019
News Conference News ACC 2018 High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab Michael O'Riordan March 20, 2018
News Conference News ACC 2017 High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI Michael O'Riordan March 21, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2016 Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH Michael O'Riordan April 03, 2016
News Conference News ACC 2016 HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not Michael O'Riordan April 02, 2016
News Conference News ACC 2013 Rosuvastatin Helps Stave Off Contrast Nephropathy in NSTE-ACS Patients L.A. McKeown March 09, 2013